Episurf Medical delivered 45% sales growth and improved losses year-over-year, driven by rapid US expansion and cost-saving measures, including pausing the EPIC-Knee trial. A SEK 90m rights issue bolstered liquidity, with a sharpened focus on US commercialization.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.